Metsera Inc. Announces Positive Phase 1 Trial Results for Once-Monthly Amylin Candidate MET-233i, Showing Promising Weight Loss and No Safety Concerns

Reuters

06-09

<a href="https://laohu8.com/S/MTSR">Metsera Inc.</a> Announces Positive Phase 1 Trial Results for Once-Monthly Amylin Candidate MET-233i, Showing Promising Weight Loss and No Safety Concerns

Metsera Inc. (Nasdaq: MTSR) has announced positive topline results from its Phase 1 clinical trial of MET-233i, a once-monthly amylin analog. The trial demonstrated up to 8.4% mean placebo-subtracted weight loss at Day 36 and a 19-day half-life supporting monthly dosing. The results indicated that MET-233i was well-tolerated with no safety signals. The company plans to continue evaluating MET-233i both as a monotherapy and in combination with MET-097i. Topline data from the ongoing trials are anticipated by late 2025 or early 2026. Metsera will host a conference call and webcast on June 9, 2025, at 8:00 A.M. Eastern Time to discuss these findings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metsera Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9465181-en) on June 09, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2542386283"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542386283\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2542386283?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-09 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542386283","market":"us","top_or_hot":-1,"title":"Metsera Inc. Announces Positive Phase 1 Trial Results for Once-Monthly Amylin Candidate MET-233i, Showing Promising Weight Loss and No Safety Concerns","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MTSR\">Metsera Inc.</a> Announces Positive Phase 1 Trial Results for Once-Monthly Amylin Candidate MET-233i, Showing Promising Weight Loss and No Safety Concerns\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Metsera Inc. (Nasdaq: MTSR) has announced positive topline results from its Phase 1 clinical trial of MET-233i, a once-monthly amylin analog. The trial demonstrated up to 8.4% mean placebo-subtracted weight loss at Day 36 and a 19-day half-life supporting monthly dosing. The results indicated that MET-233i was well-tolerated with no safety signals. The company plans to continue evaluating MET-233i both as a monotherapy and in combination with MET-097i. Topline data from the ongoing trials are anticipated by late 2025 or early 2026. Metsera will host a conference call and webcast on June 9, 2025, at 8:00 A.M. Eastern Time to discuss these findings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metsera Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9465181-en) on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Metsera Inc. Announces Positive Phase 1 Trial Results for Once-Monthly Amylin Candidate MET-233i, Showing Promising Weight Loss and No Safety Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMetsera Inc. Announces Positive Phase 1 Trial Results for Once-Monthly Amylin Candidate MET-233i, Showing Promising Weight Loss and No Safety Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-09 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MTSR\">Metsera Inc.</a> Announces Positive Phase 1 Trial Results for Once-Monthly Amylin Candidate MET-233i, Showing Promising Weight Loss and No Safety Concerns\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Metsera Inc. (Nasdaq: MTSR) has announced positive topline results from its Phase 1 clinical trial of MET-233i, a once-monthly amylin analog. The trial demonstrated up to 8.4% mean placebo-subtracted weight loss at Day 36 and a 19-day half-life supporting monthly dosing. The results indicated that MET-233i was well-tolerated with no safety signals. The company plans to continue evaluating MET-233i both as a monotherapy and in combination with MET-097i. Topline data from the ongoing trials are anticipated by late 2025 or early 2026. Metsera will host a conference call and webcast on June 9, 2025, at 8:00 A.M. Eastern Time to discuss these findings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metsera Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9465181-en) on June 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nNDL1bGJtH:1","article_id":"2542386283","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542386283","pubTimestamp":1749466819,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Metsera Inc. Announces Positive Phase 1 Trial Results for Once-Monthly Amylin Candidate MET-233i, Showing Promising Weight Loss and No Safety Concerns. Metsera Inc.  has announced positive topline results from its Phase 1 clinical trial of MET-233i, a once-monthly amylin analog. The trial demonstrated up to 8.4% mean placebo-subtracted weight loss at Day 36 and a 19-day half-life supporting monthly dosing. The results indicated that MET-233i was well-tolerated with no safety signals. The company plans to continue evaluating MET-233i both as a monotherapy and in combination with MET-097i. Topline data from the ongoing trials are anticipated by late 2025 or early 2026. Metsera will host a conference call and webcast on June 9, 2025, at 8:00 A.M. Eastern Time to discuss these findings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for infor","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4588":"碎股","BK4112":"金融交易所和数据","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4139":"生物科技","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","MTSR":"Metsera Inc.","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","NDAQ":"纳斯达克OMX交易所"},"translate_title":"Metsera Inc.宣布每月一次的胰淀素候选药物MET-233i的积极1期试验结果，显示出有希望的减肥效果，并且没有安全问题","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MTSR":0.9,"NDAQ":0.9},"content_text":"Metsera Inc. Announces Positive Phase 1 Trial Results for Once-Monthly Amylin Candidate MET-233i, Showing Promising Weight Loss and No Safety Concerns\n    \n\n        Metsera Inc. (Nasdaq: MTSR) has announced positive topline results from its Phase 1 clinical trial of MET-233i, a once-monthly amylin analog. The trial demonstrated up to 8.4% mean placebo-subtracted weight loss at Day 36 and a 19-day half-life supporting monthly dosing. The results indicated that MET-233i was well-tolerated with no safety signals. The company plans to continue evaluating MET-233i both as a monotherapy and in combination with MET-097i. Topline data from the ongoing trials are anticipated by late 2025 or early 2026. Metsera will host a conference call and webcast on June 9, 2025, at 8:00 A.M. Eastern Time to discuss these findings.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metsera Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9465181-en) on June 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}